Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2

1. A compound corresponding to formula I,

wherein

R 1 is C 1-4 -alkyl;

R 2 is C 1-4 -alkyl;

R 3 is phenyl which is optionally substituted 1 to 3 times by any of halogen, C 1-6 -alkyl or C 1-4 -alkoxy;

R 4 is hydrogen; C 1-6 -alkyl or C 3-7 -cycloalkyl-C 1-4 -alkyl,

R 6 is hydrogen; and

R 7 is hydrogen; and

R 8 is hydrogen; and

R 10 is C 1-6 -alkyl; phenyl-C 0-4 -alkyl or pyridinyl-C 0-4 -alkyl; provided that R 10 is not phenyl when R 5 and R 9 together form C 2 -alkylene;

R 5 and R 9 together form C 1-3 -alkylene; and

n is 0 or 1,

or a physiologically compatible salt thereof.

2. A compound according to claim 1 , wherein R 1 and R 2 are each methyl.

3. A compound according to claim 1 , wherein R 3 is 4-ethylphenyl.

4. A compound according to claim 1 , wherein R 4 is hydrogen, C 1-6 -alkyl or cyclopropylmethyl.

5. A compound according to claim 1 , wherein R 10 is C 1-6 -alkyl; phenyl-C 1-4 -alkyl or pyridinyl-C 1-4 -alkyl.

6. A compound according to claim 1 , wherein R 10 is benzyl or pyridinylmethyl.

7. A compound according to claim 1 , wherein said compound is selected from the group consisting of

N-{6-[2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-3-hydroxy-2,2-dimethyl-chroman-4-yl}-4-ethyl-benzenesulfonamide;

4-ethyl-N-{3-hydroxy-2,2-dimethyl-6-[2-oxo-2-(4-pyridin-3-ylmethyl-piperazin-1-yl)-ethyl]-chroman-4-yl}-benzenesulfonamide;

4-ethyl-N-{3-hydroxy-2,2-dimethyl-6-[2-oxo-2-(4-pyridin-2-ylmethyl-piperazin-1-yl)-ethyl]-chroman-4-yl}-benzenesulfonamide and

4-ethyl-N-{3-hydroxy-2,2-dimethyl-6-[2-oxo-2-(4-pyridin-4-ylmethyl-piperazin-1-yl)-ethyl]-chroman-4-yl}-benzenesulfonamide.

8. A compound according to claim 1 which is 4-ethyl-N-{3-hydroxy-2,2-dimethyl-6-[2-oxo-2-(4-pyridin-3-ylmethyl-piperazin-1-yl)-ethyl]-chroman-4-yl}-benzenesulfonamide.

9. A pharmaceutical composition, containing a pharmacologically active quantity of a compound of formula I according to claim 1 and at least one auxiliary or carrier.

10. A method of treating cardiovascular disease in a mammal or human, said method comprising administering to said mammal or human a pharmaceutically effective amount of a compound according to claim 1 .

11. The method of claim 10 , wherein the cardiovascular disease is an arrhythmia.

12. A process for the preparation of a compound corresponding to Formula I,

wherein

R 1 is C 1-4 -alkyl;

R 2 is C 1-4 -alkyl;

R 3 is phenyl which is optionally substituted 1 to 3 times by any of halogen, C 1-6 -alkyl or C 1-4 -alkoxy;

R 4 is hydrogen; C 1-6 -alkyl or C 3-7 -cycloalkyl-C 1-4 -alkyl,

R 6 is hydrogen; and

R 7 is hydrogen; and

R 8 is hydrogen; and

R 10 is C 1-6 -alkyl; phenyl-C 0-4 -alkyl or pyridinyl-C 0-4 -alkyl; with the proviso that R 10 is not phenyl when R 5 and R 9 together form C 2 -alkylene;

R 5 and R 9 together form C 1-3 -alkylene; and

n is 0 or 1,

or a physiologically compatible salt thereof,

said method comprising the steps of reacting

a) a compound corresponding to the general Formula II,

wherein R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and n have the above meanings, with a compound of the general formula III,

X—SO 2 —R 3   III

wherein R 3 has the above meaning, and X is a cleavable leaving group, or

reacting

b) a compound corresponding to general Formula IV

wherein R 1 , R 2 , R 3 and R 4 have the above meanings, with a compound corresponding to general Formula V,

wherein R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and n have the above meanings, and optionally converting resulting free compounds corresponding to Formula I into their physiologically compatible salts, or converting salts of the compounds corresponding to Formula I into free compounds corresponding to Formula I.

13. A compound corresponding to formula II,

wherein

R 1 is C 1-4 -alkyl;

R 2 is C 1-4 -alkyl;

R 4 is hydrogen; C 1-6 -alkyl or C 3-7 -cycloalkyl-C 1-4 -alkyl,

R 6 is hydrogen; and

R 7 is hydrogen; and

R 8 is hydrogen; and

R 10 is C 1-6 -alkyl; phenyl-C 0-4 -alkyl or pyridinyl-C 0-4 -alkyl; with the proviso that R 10 is not phenyl when R 5 and R 9 together form C 2 -alkylene; or

R 5 and R 9 together form C 1-3 -alkylene; and

n is 0 or 1

or a salt or solvate thereof.